41-50 of 84 results
High Court unanimously finds isolated genetic material not patentable
In the culmination of a hard-fought patent dispute the High Court of Australia has unanimously ruled that Myriad Genetics patent claims to isolated nucleic acid coding for the mutant or polymorphic BRCA1 polypeptide are not valid ...
Dixon Hospitality says cheers to Beer DeLuxe
Allens has advised Dixon Hospitality on its acquisition of the Beer DeLuxe venues in NSW and Victoria. Dixon has acquired six venues including those in the entertainment precincts of King Street ...
Allens advises Healthe Care on two major acquisitions
Allens has advised leading Australian private hospital operator Healthe Care Australia in relation to the acquisition of ASX-listed Pulse Health Limited and three hospitals in the Illawarra region ...
Allens advises Archer Capital on sale of Healthe Care
Allens has advised Archer Capital on its proposed divestment of private hospital business Healthe Care to China's Luye Medical Group. Healthe Care is Australia's third largest private hospital ...
Allens helps deliver a healthy hospital outcome
Allens has advised the Plenary Health consortium on the expansion of the existing Casey Hospital through a series of transactions that closed late last week. The expansion will significantly increa ...
Protecting innovation without patents - data exclusivity and market exclusivity
Developments in patent law and the consequential limitations on patentability for biologic medicines mean that data exclusivity and market exclusivity can be the primary protection afforded to originator biologic medicines This is most stark in the US where patent protection for biologic medicines ...
What's in a (biosimilar) name?
Because biosimilars and their reference biologic medicine are not identical whether compared to each other or even between biosimilars it is important to know which product has been used ...
Protecting investment in biologic medicines - biological medicines, biosimilars and the challenges they pose
This series of articles is directed towards the part of biotech that is pharmaceutical rather than diagnostic or bioengineering technologies and in particular towards biologic medicines ...
Allens advises financiers on Icon Group acquisition
Allens has advised Credit Suisse AG and Goldman Sachs Australia as financiers of the acquisition of the Icon Group, Australia's largest private cancer and oncology services group. The acquisition, ...
Allens advises on Australian-first dementia village
Allens has provided pro bono advice to Social Ventures Australia on the financing of the ground-breaking Korongee dementia care village. The first of its kind in Australia, the village is designed ...